CYR-064
Persistent Post-Viral Hyposmia (Partial Smell Loss)
Phase 2Active
Key Facts
Indication
Persistent Post-Viral Hyposmia (Partial Smell Loss)
Phase
Phase 2
Status
Active
Company
About Cyrano Therapeutics
Cyrano Therapeutics is pioneering a regenerative therapy for post-viral smell loss (hyposmia), a significant and growing unmet medical need exacerbated by the COVID-19 pandemic. The company's lead asset, CYR-064, recently reported positive topline safety and efficacy results from a Phase 2 trial (FLAVOR), supporting advancement into Phase 3 development planned for the second half of 2026. As a private, pre-revenue company, Cyrano is positioning itself to address a market affecting millions of patients in the U.S. alone, with no currently approved pharmaceutical treatments available. Its progress makes it a notable player in the emerging field of sensory restoration.
View full company profile